Biological Models in Radiopharmaceutical Development:
Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIM...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Dordrecht
Springer Netherlands
1996
|
| Schriftenreihe: | Developments in Nuclear Medicine
27 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals |
| Beschreibung: | 1 Online-Ressource (XI, 272 p) |
| ISBN: | 9789400901599 |
| DOI: | 10.1007/978-94-009-0159-9 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046147023 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1996 |||| o||u| ||||||eng d | ||
| 020 | |a 9789400901599 |9 978-94-009-0159-9 | ||
| 024 | 7 | |a 10.1007/978-94-009-0159-9 |2 doi | |
| 035 | |a (ZDB-2-SME)978-94-009-0159-9 | ||
| 035 | |a (OCoLC)1119015460 | ||
| 035 | |a (DE-599)BVBBV046147023 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.0757 |2 23 | |
| 084 | |a YR 2400 |0 (DE-625)154093:12905 |2 rvk | ||
| 100 | 1 | |a Lambrecht, Richard M. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Biological Models in Radiopharmaceutical Development |c by Richard M. Lambrecht |
| 264 | 1 | |a Dordrecht |b Springer Netherlands |c 1996 | |
| 300 | |a 1 Online-Ressource (XI, 272 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Developments in Nuclear Medicine |v 27 | |
| 520 | |a Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals | ||
| 650 | 4 | |a Diagnostic Radiology | |
| 650 | 4 | |a Nuclear Medicine | |
| 650 | 4 | |a Veterinary Medicine/Veterinary Science | |
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Laboratory Medicine | |
| 650 | 4 | |a Radiology, Medical | |
| 650 | 4 | |a Nuclear medicine | |
| 650 | 4 | |a Veterinary medicine | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Medical laboratories | |
| 650 | 0 | 7 | |a Modell |0 (DE-588)4039798-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Radiopharmakon |0 (DE-588)4048223-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Radiopharmakon |0 (DE-588)4048223-6 |D s |
| 689 | 0 | 1 | |a Modell |0 (DE-588)4039798-1 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401065580 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789400901605 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792338369 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-94-009-0159-9 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031527208 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-94-009-0159-9 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180485794955264 |
|---|---|
| any_adam_object | |
| author | Lambrecht, Richard M. |
| author_facet | Lambrecht, Richard M. |
| author_role | aut |
| author_sort | Lambrecht, Richard M. |
| author_variant | r m l rm rml |
| building | Verbundindex |
| bvnumber | BV046147023 |
| classification_rvk | YR 2400 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-94-009-0159-9 (OCoLC)1119015460 (DE-599)BVBBV046147023 |
| dewey-full | 616.0757 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.0757 |
| dewey-search | 616.0757 |
| dewey-sort | 3616.0757 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-94-009-0159-9 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03810nmm a2200601zcb4500</leader><controlfield tag="001">BV046147023</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1996 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789400901599</subfield><subfield code="9">978-94-009-0159-9</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-94-009-0159-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-94-009-0159-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119015460</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046147023</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.0757</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YR 2400</subfield><subfield code="0">(DE-625)154093:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lambrecht, Richard M.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biological Models in Radiopharmaceutical Development</subfield><subfield code="c">by Richard M. Lambrecht</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Dordrecht</subfield><subfield code="b">Springer Netherlands</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XI, 272 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Developments in Nuclear Medicine</subfield><subfield code="v">27</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diagnostic Radiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nuclear Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Veterinary Medicine/Veterinary Science</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Laboratory Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiology, Medical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nuclear medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Veterinary medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical laboratories</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Modell</subfield><subfield code="0">(DE-588)4039798-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Radiopharmakon</subfield><subfield code="0">(DE-588)4048223-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Radiopharmakon</subfield><subfield code="0">(DE-588)4048223-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Modell</subfield><subfield code="0">(DE-588)4039798-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401065580</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789400901605</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792338369</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-94-009-0159-9</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031527208</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-94-009-0159-9</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046147023 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:31Z |
| institution | BVB |
| isbn | 9789400901599 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031527208 |
| oclc_num | 1119015460 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XI, 272 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Springer Netherlands |
| record_format | marc |
| series2 | Developments in Nuclear Medicine |
| spelling | Lambrecht, Richard M. Verfasser aut Biological Models in Radiopharmaceutical Development by Richard M. Lambrecht Dordrecht Springer Netherlands 1996 1 Online-Ressource (XI, 272 p) txt rdacontent c rdamedia cr rdacarrier Developments in Nuclear Medicine 27 Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals Diagnostic Radiology Nuclear Medicine Veterinary Medicine/Veterinary Science Pharmacology/Toxicology Laboratory Medicine Radiology, Medical Nuclear medicine Veterinary medicine Toxicology Medical laboratories Modell (DE-588)4039798-1 gnd rswk-swf Radiopharmakon (DE-588)4048223-6 gnd rswk-swf Radiopharmakon (DE-588)4048223-6 s Modell (DE-588)4039798-1 s 1\p DE-604 Erscheint auch als Druck-Ausgabe 9789401065580 Erscheint auch als Druck-Ausgabe 9789400901605 Erscheint auch als Druck-Ausgabe 9780792338369 https://doi.org/10.1007/978-94-009-0159-9 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Lambrecht, Richard M. Biological Models in Radiopharmaceutical Development Diagnostic Radiology Nuclear Medicine Veterinary Medicine/Veterinary Science Pharmacology/Toxicology Laboratory Medicine Radiology, Medical Nuclear medicine Veterinary medicine Toxicology Medical laboratories Modell (DE-588)4039798-1 gnd Radiopharmakon (DE-588)4048223-6 gnd |
| subject_GND | (DE-588)4039798-1 (DE-588)4048223-6 |
| title | Biological Models in Radiopharmaceutical Development |
| title_auth | Biological Models in Radiopharmaceutical Development |
| title_exact_search | Biological Models in Radiopharmaceutical Development |
| title_full | Biological Models in Radiopharmaceutical Development by Richard M. Lambrecht |
| title_fullStr | Biological Models in Radiopharmaceutical Development by Richard M. Lambrecht |
| title_full_unstemmed | Biological Models in Radiopharmaceutical Development by Richard M. Lambrecht |
| title_short | Biological Models in Radiopharmaceutical Development |
| title_sort | biological models in radiopharmaceutical development |
| topic | Diagnostic Radiology Nuclear Medicine Veterinary Medicine/Veterinary Science Pharmacology/Toxicology Laboratory Medicine Radiology, Medical Nuclear medicine Veterinary medicine Toxicology Medical laboratories Modell (DE-588)4039798-1 gnd Radiopharmakon (DE-588)4048223-6 gnd |
| topic_facet | Diagnostic Radiology Nuclear Medicine Veterinary Medicine/Veterinary Science Pharmacology/Toxicology Laboratory Medicine Radiology, Medical Nuclear medicine Veterinary medicine Toxicology Medical laboratories Modell Radiopharmakon |
| url | https://doi.org/10.1007/978-94-009-0159-9 |
| work_keys_str_mv | AT lambrechtrichardm biologicalmodelsinradiopharmaceuticaldevelopment |